Fabre E, Chevret S, Piechaud J F, Rey E, Vauzelle-Kervoedan F, D'Athis P, Olive G, Pons G
Pharmacologie Pédiatrique et Périnatale, Hôpital Sain-Vincent de Paul, Université René Descartes, Paris V, France.
Br J Clin Pharmacol. 1998 Oct;46(4):395-401. doi: 10.1046/j.1365-2125.1998.00788.x.
No drug has been demonstrated to provide simultaneously appropriate sedation, safety and lack of disturbance of the measured parameters during cardiac catheterization in infants. The objective of this study was to estimate the dose of midazolam, administered rectally, that would provide a 90% probability of adequate sedation in infants during cardiac catheterization. A sedation score > or =4 (six-point scale) 30 to 60 min after dosing was rated as a success.
A double-blind, continual reassessment method using a Bayesian approach has been used. Sixteen infants were administered a single midazolam dose, within a 0.1 to 0.6 mg kg(-1) dose range.
Consecutive failures led to allocation of the highest dose to 15 out of 16 patients. The final estimated probability of failure of the 0.6 mg kg(-1) dose was 81% (95% CI: 78.5 to 84%). The time to reach a score > or =4 was longer than expected and the median duration-time at score > or =4 was shorter (15 min) than expected.
Delayed absorption and low rectal bioavailability may explain these data. Higher doses or different routes of administration may lead to the expected sedation, but the safety of doses higher than 0.6 mg kg(-1) administered rectally has not been evaluated. The therapeutic strategy for sedation of this category of infants in the hospital has now been changed based on the present results in that rectal midazolam has been abandoned in this indication.
尚无药物被证明能在婴儿心脏导管插入术期间同时提供适当的镇静效果、安全性且不干扰测量参数。本研究的目的是评估经直肠给予咪达唑仑的剂量,该剂量要能使婴儿在心脏导管插入术期间有90%的概率获得充分镇静。给药后30至60分钟镇静评分≥4分(六点量表)被评定为成功。
采用了一种使用贝叶斯方法的双盲、连续重新评估法。16名婴儿在0.1至0.6毫克/千克的剂量范围内给予单次咪达唑仑剂量。
连续失败导致16名患者中有15名被分配到最高剂量。0.6毫克/千克剂量的最终估计失败概率为81%(95%置信区间:78.5%至84%)。达到评分≥4分的时间比预期长,且评分≥4分的中位持续时间(15分钟)比预期短。
吸收延迟和直肠生物利用度低可能解释了这些数据。更高剂量或不同给药途径可能会带来预期的镇静效果,但高于0.6毫克/千克经直肠给药的安全性尚未评估。基于目前的结果,医院中这类婴儿的镇静治疗策略现已改变,即在此适应症中已放弃直肠咪达唑仑。